Jon Congleton - 22 Nov 2023 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role: Chief Executive Officer, Director
Signature: /s/ Adam Levy, Attorney-in-fact
Issuer symbol: MLYS
Transactions as of: 22 Nov 2023
Net transactions value: +$25,356
Form type: 4
Filing time: 27 Nov 2023, 16:01:13 UTC
Previous filing: 08 Sep 2023
Next filing: 15 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MLYS	Common Stock	Purchase	$25,356	+4,250	+0.41%	$5.97	1,049,068	22 Nov 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is the weighted-average purchase price, purchased in multiple transactions at prices ranging from $5.8850 to $5.9996. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Content

The price reported is the weighted-average purchase price, purchased in multiple transactions at prices ranging from $5.8850 to $5.9996. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.